FDA – Page 4 – Policy & Medicine

IOM: Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease

FDA Transparency Initiative: Draft Disclosure Policies

Astra Zeneca Seroquel Settlement and Corporate Integrity Agreement

Building a Comparative FDA May Not Lead to Effectiveness

FDA Educates Industry on Development of Orphan Drugs

GAO Recommends the FDA to Strengthen Investigation Oversight

Fox Stossel Show: Hands Off My Healthcare

Letters from Grassley: FDA to Clarify Policies on Medical Devices

Five Part Podcast Series on FDA Features John Kamp of Coalition for Healthcare Communication

FDA Official Cleared of Conflict Allegations in Heparin Contamination Case